Vardenafil Hydrochloride Tablet
Product Images NDC 71335-9696

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Vardenafil Hydrochloride (NDC 71335-9696). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713359696)

Label for Vardenafil Hydrochloride Tablets 10 mg by Bryant Ranch Prepack. The label indicates a package of 30 tablets with NDC 71335-9696-1. It includes storage instructions, child safety warnings, and identifies the manufacturer as Rivopharm SA. The BRP Pharmaceuticals logo is present with repackager details.*

FDA Label Image

Chemical Structure (Vardenafil Figure 1)

Chemical structure diagram of Vardenafil Hydrochloride, showing its molecular arrangement including multiple rings and functional groups labeled with HCl and water molecules (x HCl x 3H2O).*

FDA Label Image

Figure 1 (Vardenafil Figure 2)

This figure presents three line graphs illustrating the mean maximal change in systolic blood pressure, diastolic blood pressure, and heart rate over time. The x-axis represents the timing of vardenafil treatment before NTG administration (24 hours, 8 hours, 4 hours, 1 hour). The y-axis shows the changes in systolic BP (mmHg), diastolic BP (mmHg), and heart rate (bpm), with error bars indicating variability.*

FDA Label Image

Figure 2 (Vardenafil Figure 3)

A line graph showing the mean change in mmHg over time in hours. The graph compares placebo and vardenafil 5 mg effects under simultaneous and 6-hour separation conditions, with distinct markers for each group plotted across a 6-hour time span.*

FDA Label Image

Figure 3 (Vardenafil Figure 4)

A line graph depicting mean change in millimeters of mercury (mmHg) over time in hours (Hr) for placebo and Vardenafil 5 mg under simultaneous and 6-hour separation conditions. The graph compares pressure changes across four groups: placebo simultaneous, placebo 6-hour separation, Vardenafil 5 mg simultaneous, and Vardenafil 5 mg 6-hour separation over a 6-hour period.*

FDA Label Image

Figure 4 (Vardenafil Figure 5)

A line graph showing mean change in mmHg over 6 hours comparing placebo (Stage 1 and Stage 2) and Vardenafil at 10 mg and 20 mg doses. The x-axis represents time in hours, and the y-axis shows mean change in mmHg. The graph includes separate lines for placebo and Vardenafil treatments across two stages, illustrating changes over time.*

FDA Label Image

Figure 5 (Vardenafil Figure 6)

A line graph showing mean change in mmHg over time (hours) for Vardenafil tablets at 5 mg and 10 mg doses compared to placebo in two stages. The y-axis represents mean change in mmHg, ranging from -10 to 10, while the x-axis shows time from 0 to 6 hours. Data points for placebo and Vardenafil doses are plotted with distinct symbols and line styles. The graph depicts variable responses across the measured period.*

FDA Label Image

Figure 6 (Vardenafil Figure 7)

Line graph titled 'TERAZOSIN' depicting mean change in mmHg over time in hours. The graph compares placebo, 10 mg Vardenafil, and 20 mg Vardenafil under two conditions: 6-hour separation and simultaneous administration. Data points show changes in blood pressure measured at hourly intervals up to 6 hours.*

FDA Label Image

Figure 7 (Vardenafil Figure 8)

A line graph showing the mean change in mmHg over 6 hours for Tamsulosin with various treatments: placebo, 10 mg Vardenafil, and 20 mg Vardenafil, under both 6-hour separation and simultaneous administration conditions. Mean change in blood pressure is plotted against time in hours.*

FDA Label Image

Figure 8 (Vardenafil Figure 9)

A pharmacokinetic line graph depicting plasma concentration (µg/L) of Vardenafil Hydrochloride tablets over time in hours. The graph shows plasma concentration peaks early after administration and gradually decreases to near zero by 24 hours, with error bars indicating variability at each time point.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.